Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase IB Clear all
Completed Phase 1 Interventional

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

NCT01772797
View directory record Official record
Conditions
Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer
Interventions
LDK378, AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

NCT02559674
View directory record Official record
Conditions
Advanced Pancreatic Cancer
Interventions
Gemcitabine, Nab-paclitaxel, ALT-803
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

NCT06236425
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
Interventions
TBio-4101, Pembrolizumab, Platinum based chemotherapy, Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

NCT00003750
View directory record Official record
Conditions
Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
hu14.18-IL2 fusion protein
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
54
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

Phenoxodiol in Treating Patients With Refractory Solid Tumors

NCT00022295
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
idronoxil
Drug
Lead sponsor
Kazia Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Nov 4, 2026, 10:49 PM EST
Withdrawn Phase 2 Interventional

Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB

NCT03146039
View directory record Official record
Conditions
Cervical Cancer, Cervical Cancer Stage, Cervical Cancer Stage IB2, Cervical Cancer Stage IB1, Cervical Cancer Stage I, Cervical Cancer Stage IB, Cervical Cancer Stage II, Cervical Cancer Stage IIa, Cervical Cancer, Stage IIB, Cervical Cancer, Stage III, Cervical Cancer Stage IIIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage Iv, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 4, 2026, 10:49 PM EST
Recruiting Phase 1 Interventional

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

NCT04997993
View directory record Official record
Conditions
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Interventions
Leflunomide
Drug
Lead sponsor
Deborah Doroshow
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Nov 4, 2026, 10:49 PM EST
Active, not recruiting Phase 1 Interventional

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

NCT03220477
View directory record Official record
Conditions
Lung Cancer
Interventions
Pembrolizumab, Guadecitabine, Mocetinostat
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional Results available

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

NCT01317875
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
3
States / cities
Winter Park, Florida • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

NCT03964233
View directory record Official record
Conditions
Neoplasms
Interventions
BI 907828, ezabenlimab, BI 754111
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Athens, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 4, 2026, 10:49 PM EST
Completed Not applicable Interventional Results available

Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

NCT02002533
View directory record Official record
Conditions
Sleep Disorder, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Brief Behavioral Therapy, Telephone-Based Intervention, Educational Intervention
Behavioral · Other
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Stanford, California • Decatur, Illinois • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Nov 4, 2026, 10:49 PM EST
Completed Not applicable Interventional

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

NCT01453452
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Pain, Psychosocial Effects of Cancer and Its Treatment, Weight Changes
Interventions
behavioral dietary intervention, exercise intervention, counseling intervention, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
58
States / cities
Tucson, Arizona • Antioch, California • Fremont, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 3 Interventional Results available

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

NCT00553410
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
4,884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

NCT02535689
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Tofacitinib, Placebo
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Nov 4, 2026, 10:49 PM EST
Completed Not applicable Interventional

Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer

NCT00507923
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Breast Cancer
Interventions
Actigraph, Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Sleep Diary, Stretching, Yoga
Device · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional Results available

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

NCT02516813
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
M3814 100 mg, M3814 200 mg, M3814 300 mg, M3814 400 mg, M3814 50 mg, Fractionated RT, Cisplatin
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 4, 2026, 10:49 PM EST
Recruiting Phase 1 Interventional

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

NCT07318324
View directory record Official record
Conditions
Phase IB, Avutometinib, RAS Pathway, Endometrial
Interventions
Avutometinib, defactinib, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

NCT03373188
View directory record Official record
Conditions
Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab, Surgery
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Nov 4, 2026, 10:49 PM EST
Withdrawn Not applicable Interventional

Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer

NCT03091842
View directory record Official record
Conditions
Cancer Survivor, Central Obesity, Estrogen Receptor Positive, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Exercise Intervention, Informational Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT04520659
View directory record Official record
Conditions
RSV Infection
Interventions
RSV LID/ΔM2-2/1030s, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 4, 2026, 10:49 PM EST
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Nov 4, 2026, 10:49 PM EST
Completed Early Phase 1 Interventional

Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors

NCT03407716
View directory record Official record
Conditions
Cancer Survivor, Stage I Breast Cancer AJCC v7, Stage I Colon Cancer AJCC v6 and v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colon Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIA Colon Cancer AJCC v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7, Stage III Breast Cancer AJCC v7, Stage III Colon Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7
Interventions
American Ginseng, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Nov 4, 2026, 10:49 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

NCT04216316
View directory record Official record
Conditions
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
34
States / cities
Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 4, 2026, 10:49 PM EST